News | January 30, 2026
Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%
The base Gland business posted ?11,790 million in revenue, up 16% YoY
The base Gland business posted ?11,790 million in revenue, up 16% YoY
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
The BD Neopak Glass Prefillable Syringe platform is designed for the complex needs of biologics and combination products
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
The primary goal of the collaboration is joint research into trending and next-generation molecules
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
While Merck can appeal, Halozyme said it expects the order to hold
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)
Subscribe To Our Newsletter & Stay Updated
